Physician profile
Eli Gavi
NPI 1609049980
$4,277.00
in general payments reported to CMS, 2019-2025
37 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $300 · 2021: $121 · 2022: $423 · 2023: $693 · 2024: $1,014 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.47 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,012.57 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $343.24 | 2020-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.35 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $315.70 | 2019-2025 | Andexxa, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $306.60 | 2019-2025 | Dupixent |
| Inari Medical, INC. | $190.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $178.66 | 2019-2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $163.13 | 2019-2025 | |
| Amgen INC. | $137.75 | 2022-2025 | Tezspire |
| Abbvie INC. | $100.15 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.55 | 2020-2023 | Glassia |
| Grifols USA, LLC | $88.47 | 2022-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $83.29 | 2022-2025 | |
| Inspire Medical Systems, INC. | $74.82 | 2024-2025 | Inspire |
| Vapotherm INC | $67.37 | 2022-2023 | Vapotherm |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $66.66 | 2019 | |
| United Therapeutics Corporation | $61.32 | 2024-2025 | Tyvaso, Orenitram, Remodulin |
| Novartis Pharmaceuticals Corporation | $61.25 | 2019-2025 | |
| Gilead Sciences, INC. | $60.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $58.90 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $44.11 | 2020-2024 | Winrevair |
| Pfizer INC. | $41.43 | 2019-2023 | |
| Shionogi INC | $41.29 | 2023 | Fetroja |
| Circassia INC. | $39.21 | 2019-2020 | |
| Genentech USA, INC. | $38.94 | 2019 | |
| Mylan Specialty L.P. | $38.71 | 2019 | |
| Philips North America LLC | $35.35 | 2024-2025 | (Ae4) Secretion Management, Image Management Subscription |
| Allergan, INC. | $34.30 | 2019 | |
| Harmony Biosciences LLC | $32.64 | 2020 | |
| Pulmonx Corporation | $28.06 | 2023 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $23.12 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $22.88 | 2019 | |
| Electromed, INC. | $22.03 | 2025 | Smartvest |
| Arbor Pharmaceuticals, INC. | $14.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2020 | |
| Nabriva Therapeutics, Plc | $11.41 | 2020 | |
| Inogen, INC. | $8.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Gavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.